Mira Pharmaceuticals reports positive toxicology results for MIRA-55
The company said 7-day rat and dog studies inform dosing for the next stage of IND-enabling work as it targets a Q1 2027 IND submission.
SEC filing
Latest
1 story
Sign inSign in1 story
The company said 7-day rat and dog studies inform dosing for the next stage of IND-enabling work as it targets a Q1 2027 IND submission.
SEC filing